All Stories

  1. A conserved tryptophan in the acylated segment of RTX toxins controls their β2 integrin–independent cell penetration
  2. Outsmarting Pathogens with Antibody Engineering
  3. Discovering a Highly Conserved S2 Epitope in SARS-CoV-2 Spike Proteins
  4. SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines
  5. Engineering antibodies for conditional activity in the solid tumor microenvironment
  6. Blockade of the Adenylate Cyclase Toxin Synergizes with Opsonizing Antibodies to Protect Mice against Bordetella pertussis
  7. Structural basis for non-canonical integrin engagement by Bordetella adenylate cyclase toxin
  8. An antibody Fc engineered for conditional antibody-dependent cellular cytotoxicity at the low tumor microenvironment pH
  9. The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes
  10. Antibodies binding diverse pertactin epitopes protect mice from Bordetella pertussis infection
  11. The SARS-CoV-2 spike protein reversibly samples an open-trimer conformation exposing novel epitopes
  12. Expression and characterization of SARS-CoV-2 spike proteins
  13. Structural basis for antibody binding to adenylate cyclase toxin reveals RTX linkers as neutralization-sensitive epitopes
  14. Recombinant antibodies recognize conformation-dependent epitopes of the leucine zipper of misfolding-prone myocilin
  15. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
  16. One step ultra-high-throughput sequencing of the paired antibody VH:VL and TCRβ:α repertoires using cell lysate resistant xenopolymerase in emulsion
  17. A facile technology for the high-throughput sequencing of the paired VH:VL and TCRβ:TCRα repertoires
  18. Neutralization of pertussis toxin by a single antibody prevents clinical pertussis in neonatal baboons
  19. Human cytomegalovirus-specific T-cell receptor engineered for high affinity and soluble expression using mammalian cell display
  20. Basics of pertussis pathogenesis
  21. Humanised monoclonal antibodies neutralise pertussis toxin by receptor blockade and reduced retrograde trafficking
  22. Evaluation of Adenylate Cyclase Toxoid Antigen in Acellular Pertussis Vaccines by Using a Bordetella pertussis Challenge Model in Mice
  23. Enhancing the immunotherapeutic Trastuzumab for selective activity in the low pH tumor microenvironment
  24. Characterization of Individual Human Antibodies That Bind Pertussis Toxin Stimulated by Acellular Immunization
  25. Identification of high affinity HER2 binding antibodies using CHO Fab surface display
  26. Engineering therapeutic antibodies to combat infectious diseases
  27. When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions
  28. Charge Shielding Prevents Aggregation of Supercharged GFP Variants at High Protein Concentration
  29. De novo design of antibody complementarity determining regions binding a FLAG tetra-peptide
  30. Fine Epitope Mapping of Two Antibodies Neutralizing the Bordetella Adenylate Cyclase Toxin
  31. Passive Immunization with Anti-Pertussis Toxin Humanized Monoclonal Antibody Mitigates Clinical Signs of Pertussis Infection in Newborn Baboons
  32. Prior exposure to <i>Bordetella</i> species as an exclusion criterion in the baboon model of pertussis
  33. Viscosity Reduction of a Concentrated Monoclonal Antibody with Arginine·HCl and Arginine·Glutamate
  34. Synergistic Neutralization of Pertussis Toxin by a Bispecific AntibodyIn VitroandIn Vivo
  35. Inclusion of an RGD Motif Alters Invasin Integrin-Binding Affinity and Specificity
  36. A cocktail of humanized anti–pertussis toxin antibodies limits disease in murine and baboon models of whooping cough
  37. Rapid Fine Conformational Epitope Mapping Using Comprehensive Mutagenesis and Deep Sequencing
  38. The Bordetella adenylate cyclase repeat-in-toxin (RTX) domain is immunodominant and elicits neutralizing antibodies.
  39. Increased Fab thermoresistance via VH-targeted directed evolution
  40. Immunotherapeutic Approaches To Prevent Cytomegalovirus-Mediated Disease
  41. Structural and biophysical characterization of an epitope-specific engineered Fab fragment and complexation with membrane proteins: implications for co-crystallization
  42. The Use of Engineered Antibody Fragments to Promote Crystallization of Membrane Proteins
  43. Back to the future: recombinant polyclonal antibody therapeutics
  44. In Vivo Whole Animal Fluorescence Imaging of a Microparticle-Based Oral Vaccine Containing (CuInSexS2–x)/ZnS Core/Shell Quantum Dots
  45. Tunable equilibrium nanocluster dispersions at high protein concentrations
  46. Flanking Residues Are Central to DO11.10 T Cell Hybridoma Stimulation by Ovalbumin 323–339
  47. Antibody nanoparticle dispersions formed with mixtures of crowding molecules retain activity and In Vivo bioavailability
  48. The Skp Chaperone Helps Fold Soluble Proteins in Vitro by Inhibiting Aggregation
  49. Restriction enzyme-free construction of random gene mutagenesis libraries in Escherichia coli
  50. Crystallization chaperone strategies for membrane proteins
  51. Antibodies Recognizing Protective Pertussis Toxin Epitopes Are Preferentially Elicited by Natural Infection versus Acellular Immunization
  52. Conversion of scFv peptide-binding specificity for crystal chaperone development
  53. Characterization of a Key Neutralizing Epitope on Pertussis Toxin Recognized by Monoclonal Antibody 1B7
  54. Surface plasmon resonance for high‐throughput ligand screening of membrane‐bound proteins
  55. Crystal Structure of the Engineered Neutralizing Antibody M18 Complexed to Domain 4 of the Anthrax Protective Antigen
  56. Progress Towards Recombinant Anti-Infective Antibodies
  57. Structural evidence for a germline-encoded T cell receptor–major histocompatibility complex interaction 'codon'
  58. Modeling the structure of mAb 14B7 bound to the anthrax protective antigen
  59. High-level bacterial secretion of single-chain αβ T-cell receptors
  60. Structure of an Autoimmune T Cell Receptor Complexed with Class II Peptide-MHC
  61. Structure of an Autoimmune T Cell Receptor Complexed with Class II Peptide-MHCInsights into MHC Bias and Antigen Specificity
  62. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity
  63. In Vitro Scanning-Saturation Mutagenesis
  64. A Novel All Helix Fold of the AP180 Amino-Terminal Domain for Phosphoinositide Binding and Clathrin Assembly in Synaptic Vesicle Endocytosis
  65. Antibody Engineering
  66. Rhizoremediation of Trichloroethylene by a Recombinant, Root-Colonizing Pseudomonas fluorescens Strain Expressing Toluene ortho -Monooxygenase Constitutively